PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.20%
Both yoy net incomes decline, with VET at -59.33%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-5.11%
Negative yoy D&A while VET is 3.51%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
285.96%
Well above VET's 94.55% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
74.00%
Less working capital growth vs. VET's 893.65%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.00%
Lower 'other working capital' growth vs. VET's 893.65%. David Dodd would see fewer unexpected short-term demands on cash.
-92.71%
Both negative yoy, with VET at -191.63%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-15.63%
Negative yoy CFO while VET is 36.48%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-16.17%
Negative yoy CapEx while VET is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.74%
Both yoy lines negative, with VET at -17.42%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-510.35%
Both yoy lines negative, with VET at -17.42%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-90.48%
Negative yoy issuance while VET is 244.83%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.